Oritinib

Oritinib
Clinical data
Other names	SH-1028
Identifiers
	IUPAC name N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;
CAS Number	2035089-28-0;
PubChem CID	122666966;
Chemical and physical data
Formula	C31H37N7O2
Molar mass	539.684 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=C4CCCCN4C5=CC=CC=C53)OC;
	InChI InChI=InChI=1S/C31H37N7O2/c1-6-29(39)33-23-19-24(28(40-5)20-27(23)37(4)18-17-36(2)3)35-31-32-15-14-22(34-31)30-21-11-7-8-12-25(21)38-16-10-9-13-26(30)38/h6-8,11-12,14-15,19-20H,1,9-10,13,16-18H2,2-5H3,(H,33,39)(H,32,34,35); Key:PLUKVDOZEJBBIS-UHFFFAOYSA-N;

Oritinib is an investigational new drug currently under investigation for its potential use in cancer treatment.^[1]^[2] As a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, oritinib targets specific enzymes involved in the signaling pathways that regulate cell division and survival, which are often dysregulated in cancer cells.^[1]

References

^ ^a ^b Xiong A, Ren S, Liu H, Miao L, Wang L, Chen J, et al. (October 2022). "Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial". Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. 17 (10): 1216–1226. doi:10.1016/j.jtho.2022.06.013. PMID 35798241.
^ "Rilertinib - Nanjing Sanhome Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.